MicroRNA News and Research

RSS

In genetics, microRNAs (miRNA) are single-stranded RNA molecules of 21-23 nucleotides in length, which regulate gene expression. miRNAs are encoded by genes from whose DNA they are transcribed but miRNAs are not translated into protein (i.e. they are non-coding RNAs); instead each primary transcript (a pri-miRNA) is processed into a short stem-loop structure called a pre-miRNA and finally into a functional miRNA. Mature miRNA molecules are partially complementary to one or more messenger RNA (mRNA) molecules, and their main function is to down-regulate gene expression.

Findings may lead to new drug therapies to reduce breast cancer metastasis

Researchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROCK, a protein that was found to be over-expressed in metastatic breast cancer.

4 Nov 2009

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it presented new pre-clinical research findings from its transthyretin (TTR)-mediated amyloidosis (ATTR) program at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (“The Liver Meeting”).

2 Nov 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

2 Nov 2009

IGR Genomic Center awarded ISO 9001 certification

The Institut de cancérologie Gustave Roussy (IGR) France announced today that its Genomic Center has been awarded ISO 9001 certification for quality management and compliance to the highest standards of quality by Association Française de Normalisation (AFNOR), France’s national organization for standardization and certification.

30 Oct 2009

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today its participation in a $2.4 million research grant awarded to the University of Pennsylvania under the “American Recovery and Reinvestment Act of 2009”. The new grant will fund research over two years in the laboratories of Daniel Rader, M.D. of the University of Pennsylvania School of Medicine, Sekar Kathiresan, M.D. of Massachusetts General Hospital (MGH) and Harvard Medical School, and Alnylam.

29 Oct 2009

GeneGo to launch new web site with high quality pathway content

GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism.

29 Oct 2009

Repros Therapeutics amends its existing license for Proellex

Repros Therapeutics today announced that the Company has entered into an amendment with the National Institutes of Health (NIH) to its existing exclusive license for Proellex® that revises the existing milestones and dates for performance to provide additional time to lift the current clinical hold on Proellex or select a second generation molecule for further development from the family of anti-progestational agents covered by the license.

29 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and KOKEN Co., Ltd., a leading atelocollagen company, announced today that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.

27 Oct 2009

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

NCI implements NanoString Technologies' nCounter Analysis System

NanoString Technologies, Inc., a privately held life sciences company marketing a molecular barcoding detection system, today announced that the National Cancer Institute (NCI) is employing its nCounter™ Analysis System at two of its core labs.

From NanoString Technologies 22 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Certain molecules found to play an important role in regulating circadian rhythm: Study

Molecules that may hold the key to new ways to fight cancer and other diseases have been found to play an important role in regulating circadian rhythm, says Liheng Shi, a researcher in Texas A&M's Department of Veterinary Integrative Biosciences.

21 Oct 2009

Applied Biosystems announces the commercial availability of SOLiD 3 Plus System

Applied Biosystems, part of Life Technologies Corporation today announced the commercial availability of the SOLiD™ 3 Plus System, an enhanced next-generation genomic analysis platform designed to allow researchers to move one step closer to performing mainstream sequencing of personal genomes for clinical research and personalized medicine.

21 Oct 2009

Prometheus Laboratories introduces three new cancer diagnostic products

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the nationwide commercial launch of three new cancer diagnostic products: ProOnc TumorSource Dx, ProOnc Squamous Dx and ProOnc Mesothelioma Dx. Each of these tests is based on recently developed, highly sensitive microRNA technology.

15 Oct 2009

Researchers discover new cancer gene that causes adenoid cystic carcinoma

The cancer caused by this new cancer gene is called adenoid cystic carcinoma and is a slow-growing but deadly form of cancer. The research group can now show that the gene is found in 100% of these tumours, which means that a genetic test can easily be used to make a correct diagnosis.

14 Oct 2009

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

Data published in BMC Cancer and PLoS ONE show that microRNA (miRNA) biomarkers provide reliable and highly differentiated diagnosis from blood samples for lung cancer and multiple sclerosis.

14 Oct 2009

AACR to host its first Frontiers in Basic Cancer Research Meeting

The American Association for Cancer Research will host its first Frontiers in Basic Cancer Research Meeting in Boston from Oct. 8-11, 2009. The meeting is expected to draw nearly 500 leading scientists to present on high-profile topics like epigenetics, metastasis and systems biology, and create synergies among the many subfields of basic science.

12 Oct 2009

NIH grants over $3.8 million to Asuragen

Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.

8 Oct 2009

IRSF awards $2M for research into a cure for Rett syndrome

The International Rett Syndrome Foundation (IRSF) announced today that it is awarding grants totaling $2 million to support 18 innovative research projects in 2009. Each project will explore bold new ideas that have the potential to drive the field forward and speed the translation of research into treatments and a cure for Rett syndrome.

3 Oct 2009

MicroRNA News and Research

Further Reading

Findings may lead to new drug therapies to reduce breast cancer metastasis

Alnylam Pharmaceuticals presents new data from its transthyretin-mediated amyloidosis program

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

IGR Genomic Center awarded ISO 9001 certification

Alnylam Pharmaceuticals announces participation in a $2.4M cardiovascular disease research grant

GeneGo to launch new web site with high quality pathway content

Repros Therapeutics amends its existing license for Proellex

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Rosetta Genomics, GTG sign exclusive distribution agreement

NCI implements NanoString Technologies' nCounter Analysis System

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Certain molecules found to play an important role in regulating circadian rhythm: Study

Applied Biosystems announces the commercial availability of SOLiD 3 Plus System

Prometheus Laboratories introduces three new cancer diagnostic products

Researchers discover new cancer gene that causes adenoid cystic carcinoma

Geniom RT Analyzer provides accurate diagnosis of multiple sclerosis and lung cancer disorders

AACR to host its first Frontiers in Basic Cancer Research Meeting

NIH grants over $3.8 million to Asuragen

IRSF awards $2M for research into a cure for Rett syndrome

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News